Loading organizations...

§ Private Profile · Shenzhen, China
TriWise Capital is an investment firm.
TriWise Capital is an investment firm established in 2015, with its headquarters located in Shenzhen, China. The firm's primary focus is on venture capital and mergers and acquisitions (M&A) business, positioning it as an active participant in the private investment landscape. It engages in identifying and supporting companies through various stages of growth and strategic transitions.
As an investor, TriWise Capital has been noted for its involvement in the broader venture ecosystem. Its activities include contributing to investment portfolios, such as those associated with entities like Guangdong Technology Financial Group, and being recognized as an investor in other venture capital firms.
Key people at TriWise Capital.
TriWise Capital is an investment firm that focuses on venture capital and mergers and acquisitions (M&A) business.
TriWise Capital is headquartered in Shenzhen, China.
TriWise Capital is an investment firm that focuses on venture capital and mergers and acquisitions (M&A) business.
TriWise Capital is headquartered in Shenzhen, China.
Key people at TriWise Capital.
TriWise Capital is a private investment firm that commenced operations in 2015. Headquartered in Shenzhen, China, the firm has established itself as a participant in the regional and broader investment ecosystem. Its core activities revolve around strategic financial engagements within the private market.
The firm's investment strategy primarily centers on two key areas: venture capital and mergers and acquisitions (M&A). In the venture capital space, TriWise Capital seeks to identify and support emerging companies with growth potential, providing capital and strategic guidance. Its M&A activities involve facilitating corporate consolidations, divestitures, and other strategic transactions, aiming to create value for stakeholders.
Operating from Shenzhen, China, TriWise Capital is strategically positioned within one of the world's dynamic economic hubs. This location provides access to a diverse range of industries and innovative companies, particularly within the technology and manufacturing sectors prevalent in the region. The firm's presence in Shenzhen underscores its engagement with the local and national investment landscape.
TriWise Capital functions as an active investor within the venture capital and private equity community. Evidence indicates its involvement as an investor in other entities, such as being listed among top investors for South China Venture Capital. This suggests a role in funding and supporting other investment vehicles or companies within the broader financial network. Its participation in investment portfolios, including those associated with groups like Guangdong Technology Financial Group, further illustrates its engagement in the capital markets.
TriWise Capital has 3 tracked investments across 3 companies. The latest tracked deal is Series A in Patme Biotechnology in February 2026.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Feb 9, 2026 | Patme Biotechnology | Series A | — | — |
| Feb 1, 2022 | deepdub | $20.0M Series A | Insight Partners, George Mathew | Battery Ventures, Beringea, Bling Capital, Curious Capital, DCM, Matias Ventures, Matrix, NewView Capital, Norwest Venture Partners, Precursor Ventures, Scale Venture Partners, SOSV, Stellation Capital, Uncork Capital, Zeev Capital, Deborah LIU, Dominik Richter, Mike Krieger, Nick Caldwell, ROB Hodgkinson, Daniel Chadash, Danny Grander, Emiliano Calemzuk, Gideon Marks, Kevin Reilly, ROI Tiger, Booster Ventures, Stardom Ventures, Swift Ventures |
| Feb 1, 2022 | Endeavor BioMedicines | $100.0M Series B | Andrew LAM, TriWise Capital, Monal Mehta | Atlas Venture, Hatteras Venture Partners, Omega Funds, RA Capital, Roche Venture Fund, Patrick Enright, Perceptive Advisors, Piper Heartland Healthcare Capital, Revelation Partners, Tekla Capital Management, T. Rowe Price Associates |